Log in

Relevant bibliographies by topics / 305.5/2/0973

Academic literature on the topic '305.5/2/0973'

Author: Grafiati

Published: 26 July 2024

Last updated: 29 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Journal articles
Books
Book chapters
Conference papers

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '305.5/2/0973.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "305.5/2/0973"

1

Gómez-Amo, J. L., V. Estellés, A. di Sarra, R. Pedrós, M. P. Utrillas, J. A. Martínez- Lozano, C. González-Frias, E. Kyrö, and J. M. Vilaplana. "Operational considerations to improve total ozone measurements with a Microtops II ozone monitor." Atmospheric Measurement Techniques 5, no. 4 (April 19, 2012): 759–69. http://dx.doi.org/10.5194/amt-5-759-2012.

Full text

Abstract:

Abstract. A Microtops II "ozone monitor" with UV channels centered at 305.5, 312.5, and 320 nm has been used routinely in six experimental campaigns carried out in several geographic locations and seasons, covering latitudes from 35 to 68° N during the last ten years (2001–2011). The total ozone content is retrieved by Microtops II by using different combinations (Channel I, 305.5/312.5 nm; Channel II, 312.5/320 nm; and Channel III, 305.5/312.5/320 nm) of the signals at the three ultraviolet wavelengths. The long-term performance of the total ozone content determination has been studied taking into account the sensitivities to the calibration, airmass, temperature and aerosols. When a calibration was used and the airmass limit was fixed to 3, the root mean square deviations of the relative differences produced by Microtops II with respect to several Brewers are 0.9, 2, and 2% respectively for the Channel I, Channel II, and Channel III retrieval. The performance of the Microtops retrieval has been stable during the last ten years. Channel I represents the best option to determine the instantaneous total ozone content. Channels II and III values appear weakly sensitive to temperature, ozone content, and aerosols. Channel II is more stable than Channel I for airmasses larger than 2.6. The conclusions do not show any dependence on latitude and season.

APA, Harvard, Vancouver, ISO, and other styles

2

LoRusso, Patricia, Geoffrey Shapiro, Shuchi Sumant Pandya, Eunice Lee Kwak, Cheryl Jones, Marcia Belvin, Luna C. Musib, et al. "A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 2566. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.2566.

Full text

Abstract:

2566 Background: Both RAS/RAF/MEK and PI3K/Akt signaling pathways are deregulated in many tumor types. Targeting both pathways may be more efficacious than targeting either pathway alone. In preclinical models, concurrent administration of GDC‑0973, a potent, selective, MEK1/2 inhibitor and GDC-0941, a potent class I PI3K inhibitor, shows improved efficacy compared to either agent alone dosed continuously or intermittently. Methods: A phase Ib dose-escalation study with 3+3 design was initiated in patients (pts) with advanced solid tumors to evaluate the safety and pharmacokinetics (PK) of oral dosing of GDC-0973 and GDC-0941. Pts received: concurrent GDC-0973 + GDC-0941 once daily (qd) on a 21 day on/7 day off (21/7) schedule; intermittent GDC-0973 on Days 1, 4, 8, 11, 15, 18 of a 28 day cycle + GDC-0941 qd on a 21/7 schedule (MEK int); or GDC-0973 + GDC-0941 qd on a 7 day on /7 day off schedule (7/7). Starting doses were 20 mg GDC-0973 + 80 mg GDC-0941 (21/7), 100 mg GDC-0973 + 130 mg GDC-0941 (MEK int); 40 mg GDC-0973 + 130 mg GDC-0941 (7/7). Serial plasma PK samples, FDG-PET, and CT scans were obtained. Results: 78 pts have enrolled. DLTs were G3 lipase (n=1), G4 CPK elevation (n=1). Compared to the 21/7 MTD of 40 mg GDC-0973 + 100 mg GDC-0941, higher doses of GDC-0973 + GDC-0941 were tolerated on the MEK int schedule. Overall, adverse events related to the study drug combination in ≥ 20% pts were diarrhea, rash, nausea, fatigue, vomiting, decreased appetite, dysgeusia, and elevated CPK. Preliminary analysis indicated PK of GDC-0973 and GDC-0941 are not altered when dosed in combination. Of 46 evaluable pts, 26 had an FDG-PET partial metabolic response (≥ 20% decrease in mean SUVmax from baseline) at ≥1 time points. Partial responses were observed in 3 pts (mBRAF melanoma, mBRAF pancreatic ca, mKRAS endometrioid ca); 5 pts had stable disease ≥ 5 months. Conclusions: Combination dosing of GDC‑0973 and GDC-0941 is generally well tolerated, with toxicities similar to those observed in single agent GDC-0973 and GDC-0941 phase 1 trials. There are early signs of anti-tumor activity. Dose escalation on MEK int and 7/7 schedules continues and updated data will be presented.

APA, Harvard, Vancouver, ISO, and other styles

3

Padua, Rose Ann, Laure Sarda-Mantel, Mathieu Chiquet, Claire Kappel, Patricia Krief, Niclas Setterblad, Fortune Hontonnou, et al. "BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to Treatment." Blood 132, Supplement 1 (November 29, 2018): 5497. http://dx.doi.org/10.1182/blood-2018-99-114212.

Full text

Abstract:

Abstract Introduction: Targeted drugs are needed for HR-MDS/AML, particularly in elderly patients and Venetoclax, approved for some CLL, gives promising results in elderly AML. Assays to predict response to treatment may enable us to deliver personalized treatment. We sought to determine the most informative assay to predict response; viability assays can directly measure the effects of reagents on growth. Progenitor assays can potentially determine if the reagents can target diseased primitive cells. PET scanning can be used to follow response to treatment. Methods: Peripheral blood (PB) or bone marrow (BM) from 7 MDS/AML patients were incubated in a) no treatment, b) ABT-199 (1 µM) (Abbvie), c) GDC-0973 (1 µM) (Genentech) or d) ABT-199+GDC-0973 (1 µM of each) and assessed for viability using the MTT assay (n=2); cell death followed using the Incucyte® Zoom System (Essen Bioscience) (n=2) or methocult progenitor assays (Stem Cell Technologies) (n=4). Having shown that RAS:BCL-2 co-localization correlated with prognosis in MDS/AML patients (Leuk Res 37:312-9, 2013), immunofluorescence was undertaken. A micro PET device dedicated to mice was used to measure BM blast proliferation. After injection of 18F-FLT(a thymidine analogue) in mice untreated (n=7) or ABT-199 (75mg/kg)+GDC-0973(10mg/kg) treated (n=5) normal FVB/N, HR-MDS mice treated with vehicle (n=4), 2-month old HR-MDS before (n=5) and 3-month old before (n=4) and after ABT-199 (75mg/kg)+GDC-0973(10mg/kg) treatment (n=8), PET imaging was performed (Inveon Siemens Medical Systems), analyzed for signal and quantified. Results: Patient details and results are summarized on Table 1. Using the MTT assay 2 PB patient samples were found to be sensitive to ABT-199 treatment (Figure 1A, AS, p=0.00042 and YA, 0.00002) and more sensitive to the combination compared to untreated (AS, p=0.00007 and YA, 0.000003). With the incucyte the BM of one patient (AE) was found to be resistant to both ABT-199 and GDC-0973, but sensitive to the combination (Figure 1B). PB and BM from patient JA were assayed for apoptosis with the incucyte and were found to be sensitive to ABT-199 with increased apoptosis, resistant to GDC-0973 with decreased apoptosis and sensitive to the combination. Four bone marrow samples were tested in the 4 conditions using the progenitor assay (Figure 1C). Three patients were sensitive to GDC-0973, inhibiting any colony formation and the fourth had reduced colony numbers. In this assay patient JA appeared to be sensitive to GDC-0973 treatment whereas the incucyte assay scored this sample to be resistant to apoptosis; thus the cytotoxic effects of GDC-0973 may not be via apoptopsis. As the progenitor assay is likely to score the primitive disease population, this assay may prove more informative than the others without prior selection. One patient (DH) was clearly resistant to ABT-199, whereas the other three (JA, CB and FL) had reduced colony growth. All patients were sensitive to the combination treatment and inhibited colony growth. The RAS:BCL-2 co-localization in the PB revealed no complex in either the Mito or PM upon treatment with ABT-199 alone and some localization in the Mito with GDC-0973. With both ABT-199 and GDC-0973, there were hardly any cells confirming the cytotoxic effects of the combination. As we have previously shown that PM co-localization of the complex is associated with drug resistance (Blood 130:2613, 2017Suppl), we used the combination on our HR-MDS mouse model, where the complex co-localizes in the PM and followed the mice by PET scanning (Figure 1D). Weak signal was visualized in the femurs of untreated and ABT-199+GDC-0973 treated FVB/N mice (FBR 1.17+/-0.34 and 1.02+/-0.08 respectively). Mild PET signal was seen in the femurs of 2 month-old HR-MDS mice, (FBR 1.79+/-0.98). Intense PET signal was seen in the femurs and proximal humerus of HR-MDS mice treated with vehicle (3 month-old, FBR=2.35+/-1.32). Low PET signals were seen in the femurs of 5/8 HR-MDS mice treated with ABT-199+GDC-0973 (FBR=1.93+/-0.84). FBRs of the 3 groups of HR-MDS mice were significantly higher than those of FBV/N groups. Conclusion: Combined Venetoclax (ABT-199) and GDC-0973 targets MDS/AML progenitors and can potentially overcome drug resistance with the disruption of the RAS:BCL-2 complex. Bone marrow disease progression in HR-MDS mice can be monitored with 18F-FLT-PET imaging; PET data shows that the combination slows down disease progression. Disclosures Padua: Abbvie: Research Funding; Genentech: Research Funding. Giraudier:Novartis: Research Funding. Konopleva:Stemline Therapeutics: Research Funding. Andreeff:Oncoceutics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; United Therapeutics: Patents & Royalties: GD2 inhibition in breast cancer ; Reata: Equity Ownership; Celgene: Consultancy; Jazz Pharma: Consultancy; Oncolyze: Equity Ownership; Amgen: Consultancy, Research Funding; Eutropics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Aptose: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Daiichi-Sankyo: Consultancy, Patents & Royalties: MDM2 inhibitor activity patent, Research Funding; SentiBio: Equity Ownership; Astra Zeneca: Research Funding.

APA, Harvard, Vancouver, ISO, and other styles

4

Ali Khan, Mohd Wajid. "Optimization of methods for peripheral blood mononuclear cells isolation and expansion of human gamma delta T cells." Bioinformation 17, no. 3 (March 31, 2021): 460–70. http://dx.doi.org/10.6026//97320630017460.

Full text

Abstract:

Human Vγ9/Vδ2 T cells (γδ T cells) are immune surveillance cells both in innate and adaptive immunity and are a possible target for anticancer therapies, which can induce immune responses in a variety of cancers. Small non-peptide antigens such as zoledronate can do activation and expansion of T cells in vitro. It is evident that for adoptive cancer therapies, large numbers of functional cells are needed into cancer patients. Hence, optimization of methods needs to be carried out for the efficient expansion of these T cells. Standardization of peripheral blood mononuclear cells (PBMCs) isolation was devised. Cytokines (interleukin 2 (IL-2) and interleukin 15 (IL-15)) and zoledronate were also standardized for different concentrations. It was found that an increased number of PBMCs were recovered when washing was done at 1100 revolution per minute (rpm). Significantly high expansion fold was (2524 ± 787 expansion fold) achieved when stimulation of PBMCs was done with 1 μM of zoledronate and both cytokines IL-2 and IL-15 supported the expansion and survival of cells ISSN 0973-2063 (online) 0973-8894 (print) Bioinformation 17(3): 460-469 (2021) ©Biomedical Informatics (2021) 461 at the concentrations of 100 IU/ml and 10 ng/ml respectively. 14-day cultures showed highly pure (91.6 ± 5.1%) and live (96.5 ± 2.5%) expanded γδ T cells. This study aimed to standardize an easy to manipulate technique for the expansion of γδ T cells, giving a higher yield.

APA, Harvard, Vancouver, ISO, and other styles

5

Ranjbar, M., E. Aghaie, M. R. Hosseini, Mohammad Pazouki, and F. Ghavipanjeh. "Optimization of Kaolin Bioleaching by Aspergillus niger." Advanced Materials Research 20-21 (July 2007): 115–18. http://dx.doi.org/10.4028/www.scientific.net/amr.20-21.115.

Full text

Abstract:

In this paper, a central composite design was applied to optimize the bioleaching of iron from a kaolin sample containing 2.2% iron impurity by Aspergillus niger isolated from pistachio shell. The strains were inoculated into 500 ml flasks containing 100 ml media consisted of (g/l): sucrose 120; NH4NO3 0.45; KH2PO4 0.1; MgSO4.7H2O 0.3; FeSO4.7H2O 10-4; ZnSO4.7H2O 25×10- 5. The effects of initial pH, sugar and spore concentrations on iron removal extent were investigated. The two-level factorial design points were pH 2 and 5, sugar conc. 70 g/l and 130 g/l, spore conc. 9×107 and 35×107 spores/l. Also, the increase of dissolved iron, oxalic acid concentration, changes in pH value, and sugar concentration were registered. Consequently, after 10 days, the iron concentration of the best condition reached to 179.3 ppm that means 38.8% of the total iron content is removed. Furthermore, the data analysis showed that all the factors are significant, and the iron removal extent increases by increasing the initial pH to 4.4, sucrose content to 93.8 g/l, and spore concentration to 305.5 spores/μl, but further increase in each factor value has negative effect on the response.

APA, Harvard, Vancouver, ISO, and other styles

6

Anandakumar, K., and P. Veerasundari. "Simultaneous Estimation of Paracetamol, Ambroxol Hydrochloride, Levocetirizine Dihydrochloride, and Phenylephrine Hydrochloride in Combined Tablet Formulation by First-Order Derivative Spectrophotometry." ISRN Spectroscopy 2014 (March 30, 2014): 1–8. http://dx.doi.org/10.1155/2014/248960.

Full text

Abstract:

Paracetamol, ambroxol hydrochloride, levocetirizine dihydrochloride, and phenylephrine hydrochloride are used in combination for the treatment of chronic sinusitis, rhinitis, fever, nasal discharge, sore throat, and wheezing. The present work deals with method development for simultaneous estimation of paracetamol, ambroxol hydrochloride, levocetirizine dihydrochloride, and phenylephrine hydrochloride in tablet formulation by first-order derivative spectrosphotometry. For determination of sampling wavelength, 10 μg/mL of each of paracetamol, ambroxol hydrochloride, levocetirizine dihydrochloride, and phenylephrine hydrochloride was scanned in 200–400 nm ranges and sampling wavelengths were found to be 305.5 nm for paracetamol, 321 nm for ambroxol hydrochloride, 244 nm for levocetirizine dihydrochloride, and 280 nm for phenylephrine hydrochloride in first-order derivative spectrophotometry. In this method, linearity was observed in the ranges of 20–140 μg/mL for paracetamol and 10–70 μg/mL for ambroxol hydrochloride, levocetirizine dihydrochloride, and phenylephrine hydrochloride. The % recovery was within the range between 98 and 102%, and % relative standard deviation for precision and accuracy of the method was found to be less than 2%. The method is validated as per International Conference on Harmonization Guidelines. The method can be successfully applied for the simultaneous analysis of these drugs in pharmaceutical dosage forms.

APA, Harvard, Vancouver, ISO, and other styles

7

Lieven, Elena V. M., Julian M. Pine, and Helen Dresner Barnes. "Individual differences in early vocabulary development: redefining the referential-expressive distinction." Journal of Child Language 19, no. 2 (June 1992): 287–310. http://dx.doi.org/10.1017/s0305000900011429.

Full text

Abstract:

ABSTRACTThe existence of stylistic variation between children in the early stages of language acquisition has been most frequently studied using Nelson's 0973) referential—expressive distinction. While the use of this distinction has generated a great deal of interesting research, there are a number of major problems associated with it. The present study presents a simple scheme, based on formal categories, for coding stylistic variation in the early lexicon. When applied to the first 50 and 100 words of 12 children collected between 0; 11 and 2; 3, the major dimensions of difference are found to be the relative proportion of common nouns and the relative proportion of frozen phrases. Moreover, the proportion of frozen phrases is also found to be significantly positively related to children's early productivity, suggesting that, rather than being a ‘deadend’ in early language development, the acquisition of frozen phrases may provide an alternative route into multiword speech.

APA, Harvard, Vancouver, ISO, and other styles

8

Yue, Qing, Wei Han, and Zi-ling Liu. "Endoscopic reintervention after unilateral metal stent deployment for MHBO using SIS method." Medicine 102, no. 30 (July 28, 2023): e34467. http://dx.doi.org/10.1097/md.0000000000034467.

Full text

Abstract:

Endoscopic biliary drainage is the main treatment for unresectable malignant hilar biliary obstruction (MHBO). Recurrent biliary obstruction (RBO) often occurs after unilateral metal stent deployment. Endoscopic reintervention can be complex for this problem, especially for drainage of the contralateral bile duct. The stent-in-stent (SIS) method is a possible solution to this problem. Our objective was to evaluate the safety and feasibility of the SIS method for endoscopic reintervention in patients with RBO due to MHBO after unilateral metal stent deployment. Eleven patients with MHBO received endoscopic reintervention using the SIS method to manage RBO after unilateral metal stent deployment. Clinical data, including technical and clinical success, procedure time, adverse events and complications, stent patency, RBO of the revisionary stent, and survival time were recorded. Nine patients (82%) achieved technical success, and all 9 of them also achieved clinical success. The 2 unsuccessful cases received percutaneous transhepatic cholangial drainage. The median procedure time was 73 minutes. The 3 adverse events were post-endoscopic retrograde cholangiopancreatography pancreatitis, cholangitis, and liver abscess. 6 patients (67%) experienced RBO of the revisionary stent, the median time to RBO of the revisionary stent was 95.5 days, the median survival time after reintervention was 111 days, and the median overall survival time was 305.5 days. Endoscopic reintervention after previous unilateral metal stent deployment using the SIS method appears to be safe and technically feasible for MHBO patients who experience RBO.

APA, Harvard, Vancouver, ISO, and other styles

9

Kerins, Paul J., Roger A. Vertrees, Karen A. Finn, Jonathan H. Cilley, and Anthony J. DelRossi. "Comparison of Two Colloid Constituents in Prime Solutions and the Effect on Blood Loss Following Cardiopulmonary Bypass." Journal of ExtraCorporeal Technology 21 (1989): 11–14. http://dx.doi.org/10.1051/ject/198921s011.

Full text

Abstract:

A retrospective study was conducted on a population of 24 patients who had undergone coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB). This population is divisible into two groups that differ in prime constituents. Group A used 500cc of 6% Hydroxyethyl starch (Hespan) as the colloid, and Group B used 150cc of 25% albumin. No statistically significant differences were found in the preoperative demographics. All of these cases were done using the same perfusion technique and equipment. Intraoperative values displayed levels of significant difference (p <.05) between the two groups with respect to 1) bypass platelet count; and 2) greater usage of protamine in Group A. Group A Hespan = Platelet count x 1000/ml was 99.90+/-32.4, Blood loss (cc's) was 1033.3+/-305.5, Protamine:Heparin ratio was 1.41:1.0 +/- .37 Group B Albumin = Platelet count x 1000/ml was 153.84 +/- 34.17; Blood loss was 929.6+/- 105.4; Protamine:Heparin ratio was 1.01:1.0 +/- .43 In the postoperative phase which ended when the chest tube was removed, levels of significant difference were as follows: Group A Hespan = Platelet Ct.#2 x 1000/ml was 124.87 +/- 30.62, Blood loss (cc's) was 1390.25 +/- 405.78, PPF Admin. ratio was 1417 +/- 506.32. Group B Albumin= Platelet count x 1000 ml was 159.71 +/- 41.22; Blood loss= 1087.0 +/- 385.72, PPF Admin. ratio was 875 +/- 291.94. From this study it seems as though there are two factors contributing to the increased blood loss seen in Group A that may result from Hespan usage - the intraoperative and postoperative decreased platelet count and the increased amount of protamine used. Furthermore, Group A patients required substantially more PPF postoperatively.

APA, Harvard, Vancouver, ISO, and other styles

10

Izquierdo, César. "René VIRGOULAY (ed.), Le Christ de Maurice Blondel, Desclée, Paris 2003, 229 pp., 15 x 22, ISBN 2-7189-0973-0." Scripta Theologica 36, no. 1 (November 30, 2017): 336. http://dx.doi.org/10.15581/006.36.13845.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "305.5/2/0973"

1

LaBrash, Betty Brehmer. The Brehmer/Fenske family history. Decorah, Iowa: Anundsen Pub. Co., 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Curry, Patricia B., Sesh Iyengar, Pamela A. Maloney, and Marco Maroni, eds. Methods of Pesticide Exposure Assessment. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4899-0973-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Frances, Lannon, Preston Paul 1946-, and Carr Raymond, eds. Elites and power in twentieth-century Spain: Essays in honor of Sir Raymond Carr. Oxford [England]: Clarendon Press, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

G, Shibley Robert, ed. Placemaking: The art and practice of building communities. New York: Wiley, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Domhoff, G. William. Who rules America?: Challenges to corporate and class dominance. 6th ed. Boston: McGraw Hill Higher Education, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Domhoff, G. William. Who rules America?: Challenges to corporate and class dominance. 6th ed. Boston: McGraw Hill Higher Education, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Domhoff, G. William. Who rules America?: Power and politics in the year 2000. 3rd ed. Mountain View, Calif: Mayfield Pub. Co., 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Domhoff, G. William. Who rules America?: Power, politics, and social change. 6th ed. Boston: McGraw-Hill Higher Education, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Domhoff, G. William. Who rules America?: Challenges to corporate and class dominance. 6th ed. Boston: McGraw Hill Higher Education, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Domhoff, G. William. Who rules America?: Power and politics. 4th ed. Boston: McGraw Hill, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "305.5/2/0973"

1

Hickey, Pierce, Mark Roantree, Alan Crilly, and John Murphy. "Architectural Issues For Integrating Legacy Systems Using CORBA 2 in the LIOM Project." In OOIS’96, 135–51. London: Springer London, 1997. http://dx.doi.org/10.1007/978-1-4471-0973-0_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Chakraborty, Tapash, and Pekka Pietiläinen. "Excitations in the Fractional Quantum Hall Effect at ν=1/2: Layered Electron Systems." In Recent Progress in Many-Body Theories, 113–18. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4613-0973-4_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

"Front Matter." In Handbook of Immunological Investigations in Children, iii. Elsevier, 1990. http://dx.doi.org/10.1016/b978-0-7236-0973-5.50002-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Watson, J. Graham, and A. Graham Bird. "Infections and immunizations." In Handbook of Immunological Investigations in Children, 137–70. Elsevier, 1990. http://dx.doi.org/10.1016/b978-0-7236-0973-5.50016-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Sulemanji, Demet, Robert M. Kacmarek, and Yandong Jiang. "Manual and Mechanical Ventilators." In The MGH Textbook of Anesthetic Equipment, 49–71. Elsevier, 2011. http://dx.doi.org/10.1016/b978-1-4377-0973-5.10005-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Chatburn, Jennifer A., and Warren S. Sandberg. "Patient Warming Devices." In The MGH Textbook of Anesthetic Equipment, 263–70. Elsevier, 2011. http://dx.doi.org/10.1016/b978-1-4377-0973-5.10019-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Lintner, Rebecca N., and Robert S. Holzman. "Pediatric Considerations." In The MGH Textbook of Anesthetic Equipment, 297–308. Elsevier, 2011. http://dx.doi.org/10.1016/b978-1-4377-0973-5.10022-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Sandberg, Warren S., Richard D. Urman, and Jesse M. Ehrenfeld. "Preface." In The MGH Textbook of Anesthetic Equipment, ix. Elsevier, 2011. http://dx.doi.org/10.1016/b978-1-4377-0973-5.10036-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Jamil, George Leal. "Numbers Can Restrict Results?" In Handbook of Research on Information Management for Effective Logistics and Supply Chains, 1–22. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-0973-8.ch001.

Full text

Abstract:

This chapter intends to evaluate how mixed researches are significant knowledge producers for business management. A discussion is conducted about the trade-off around the success and restrictions offered by the dominance of quantitative methods, especially when there is interest to study supply management and logistics. Quantitative methods are essential for any kind of management, but, as more dynamics in market competition produces more complex scenarios, qualitative answers are needed, along its approaches to formulate new questions that will help organizational decision-makers to apply knowledge for their planning activities. This chapter will explore three main points: 1) how the excessive concentration on quantitative methods can restrict managerial views; 2) how any organization can apply qualitative methods to enrich results observed from quantitative, resulting in better, more sustainable decisions; and 3) how qualitative and quantitative methods, associated, can implement this approach in real cases, with an overview of mixed scientific research methodologies.

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "305.5/2/0973"

1

Rosen, Lee, Patricia LoRusso, Wen Wee Ma, Johathan Goldman, Amy Weise, A. Dimitrios Colevas, Alex Adjei, et al. "Abstract 4716: A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4716.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Bartley-Cho, Jonathan D., Tod Palm, and Vipul Ranatunga. "Overview of Composite Airframe Life Extension Program Project 2: Tools For Assessing The Durability And Damage Tolerance Of Fastened Composite Joints." In 2018 AIAA/ASCE/AHS/ASC Structures, Structural Dynamics, and Materials Conference. Reston, Virginia: American Institute of Aeronautics and Astronautics, 2018. http://dx.doi.org/10.2514/6.2018-0973.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Williams, Simon, Jill Fredrickson, Meghan Mckenzie, Cheryl Jones, Mary Gates, Klaus Hoeflich, Patricia LoRusso, et al. "Abstract 1280: Preclinical and Clinical Evidence for MEK Pathway Inhibition by GDC-0973 using FDG-PET." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-1280.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Musib, Luna, Steve Eppler, Edna Choo, Alan Deng, Dale Miles, Bih Hsu, Lee Rosen, et al. "Abstract 1304: Clinical pharmacokinetics of GDC-0973, an oral MEK inhibitor, in cancer patients: data from a Phase 1 study." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-1304.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Bendell, Johanna, Patricia LoRusso, Eunice Kwak, Susan Pandya, Luna Musib, Cheryl Jones, Alex De Crespigny, et al. "Abstract LB-89: Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study in patients with advanced solid tumors." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-lb-89.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!